MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target

$53.87

+0.76 (+1.43%)

(As of 02:38 PM ET)

MoonLake Immunotherapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 11 Analyst Ratings

Based on 11 Wall Street analysts who have issued ratings for MoonLake Immunotherapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 2 have given a hold rating, and 9 have given a buy rating for MLTX.

Consensus Price Target

$80.45
49.35% Upside

High Forecast	$104.00
Average Forecast	$80.45
Low Forecast	$62.00

According to the 11 analysts' twelve-month price targets for MoonLake Immunotherapeutics, the average price target is $80.45. The highest price target for MLTX is $104.00, while the lowest price target for MLTX is $62.00. The average price target represents a forecasted upside of 49.35% from the current price of $53.87.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	10 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)
Hold	2 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$80.45	$78.67	$74.46	$58.80
Forecasted Upside	49.35% Upside	60.74% Upside	51.08% Upside	31.73% Upside

“I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!” (Ad)

Starting Monday, September 23 — a veteran 25-year Chicago Options Exchange market-maker will show you his UOA options secret that could help you consistently target gains of 126%… 245%… even 463% or more… Often in 30 days or less… No matter what the market is doing right now.

Go here for the full details now.

MLTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MLTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

MoonLake Immunotherapeutics Stock vs. The Competition

Type	MoonLake Immunotherapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.82	2.77	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	49.49% Upside	979.20% Upside	6.57% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/12/2024	Needham & Company LLC 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$62.00 ➝ $62.00	+33.56%
9/12/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00	+115.42%
9/9/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight
8/26/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
6/25/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$104.00	+168.66%
4/2/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$62.00	+27.57%
Why You Should NOT Trade This Market (Ad) You'll be interested in our 5-Day Options Trading Challenge, starting September 23. So, what makes this different from every other options research you may have seen? Well, for starters... most of them want you to first BUY their service... which is usually thousands of dollars... Just click here to get the full details on the 5-Day Options Trading Challenge, before this offer go
3/13/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$92.00	+84.85%
2/26/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$92.00	+76.52%
12/18/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$66.00 ➝ $69.00	+14.56%
12/8/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$72.00	+30.32%
11/15/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$70.00 ➝ $77.00	+90.83%
9/14/2023	Bryan, Garnier & Co Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
9/12/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$41.00 ➝ $59.00	+12.12%
6/27/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$36.00 ➝ $68.00	+47.99%
6/26/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$28.00 ➝ $56.00	+21.87%
5/4/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
12/21/2022	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Katkhuda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
11/11/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$16.00	+93.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:12 PM ET.

MLTX Forecast - Frequently Asked Questions

What is MoonLake Immunotherapeutics' forecast for 2024?: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for MoonLake Immunotherapeutics is $80.45, with a high forecast of $104.00 and a low forecast of $62.00.
Should I buy or sell MoonLake Immunotherapeutics stock right now?: 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MoonLake Immunotherapeutics in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MLTX shares.
Does MoonLake Immunotherapeutics's stock price have much upside?: According to analysts, MoonLake Immunotherapeutics's stock has a predicted upside of 64.47% based on their 12-month stock forecasts.
Has MoonLake Immunotherapeutics been downgraded by Wall Street analysts recently?: Over the previous 90 days, MoonLake Immunotherapeutics's stock had 1 downgrade by analysts.
What analysts cover MoonLake Immunotherapeutics?: MoonLake Immunotherapeutics has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, Needham & Company LLC, Oppenheimer, and Wolfe Research in the past 90 days.
Do Wall Street analysts like MoonLake Immunotherapeutics more than its competitors?: Analysts like MoonLake Immunotherapeutics more than other "medical" companies. The consensus rating score for MoonLake Immunotherapeutics is 2.82 while the average consensus rating score for "medical" companies is 2.77. Learn more on how MLTX compares to other companies.